Overview

Birinapant and Carboplatin in Treating Patients With Recurrent High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Status:
Withdrawn

Trial end date:
2021-02-01

Target enrollment:

Participant gender:

Summary

This phase I/II trial studies how well birinapant and carboplatin work in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that has come back. Drugs used in chemotherapy, such as birinapant and carboplatin work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Jonsson Comprehensive Cancer Center

Collaborators:

Alpha Stem Cell Clinic (ASCC)
California Institute for Regenerative Medicine (CIRM)
TetraLogic Pharmaceuticals

Treatments:

Albumin-Bound Paclitaxel
Carboplatin
Paclitaxel